IQVIA Holdings Earnings Call Signals AI-Driven Growth

IQVIA Holdings ((IQV)) has held its Q4 earnings call. Read on for the main highlights of the call.

IQVIA Holdings’ latest earnings call struck a broadly upbeat tone, as management highlighted a clear recovery in R&D demand, robust bookings, and record backlog alongside healthy revenue and EPS growth. While they acknowledged pockets of risk from higher cancellations, margin pressure, and elevated leverage, executives repeatedly emphasized strong secular tailwinds and growing opportunities to monetize AI‑driven, integrated solutions.

Full-Year Revenue and EPS Momentum

IQVIA reported 2025 revenue of $16.31 billion, rising 5.9% on a reported basis and 4.8% in constant currency, underscoring steady top-line expansion despite a choppy macro backdrop. Adjusted diluted EPS climbed 7.1% year over year to $11.92, signaling operating discipline and earnings leverage even as certain cost and mix headwinds weighed on margins.

Q4 Delivers Double-Digit Top-Line Growth

Fourth-quarter performance was particularly strong, with revenue reaching $4.34 billion, up 10.3% reported and 8.1% at constant currency, including roughly two percentage points from acquisitions. Adjusted diluted EPS for Q4 rose 9.6% to $3.42, reflecting solid execution across segments and confirming the demand recovery seen in late 2025.

R&D Recovery Fuels Bookings and Backlog

R&D demand clearly turned a corner, as Q4 net bookings exceeded $2.7 billion, growing 7% year on year and 5% sequentially, for a net book-to-bill ratio of 1.18. Backlog reached a record $32.7 billion, up 5.3% versus last year, with $8.3 billion expected to convert to revenue over the next 12 months, giving the company solid visibility into 2026.

Strong Cash Generation and Capital Returns

For the full year, IQVIA generated roughly $2.51 billion in free cash flow, equating to about 99% of adjusted net income and underscoring the cash-generative nature of the model. In Q4, operating cash flow came in at $735 million and free cash flow at $561 million, while the company repurchased $1.244 billion of stock in 2025 at an average price of $159, signaling confidence in long-term value.

Segment Performance Highlights Balanced Growth

In Q4, Technology & Analytics Solutions revenue reached $1.821 billion, up 9.8% reported and 7.1% in constant currency, while R&D Solutions delivered $2.33 billion, up 9.1% reported and 8.2% in constant currency, reflecting broad-based demand. The CSMS unit posted standout growth with $210 million of revenue, up 18.6% reported and 15.3% in constant currency, and on a recast 2025 basis IQVIA reported $6.73 billion in Commercial Solutions revenue and $9.57 billion in R&D Solutions.

Constructive 2026 Guidance and Earnings Outlook

For 2026, management guided revenue to a range of $17.159 billion to $17.359 billion, including about 150 basis points of growth from M&A and a 100 basis-point FX tailwind, alongside adjusted EBITDA of $3.975 billion to $4.25 billion. Adjusted diluted EPS is expected between $12.55 and $12.85, supported by an effective tax rate just over 17%, operating D&A of roughly $610 million, net interest expense around $760 million, and average diluted shares slightly above 171 million.

Strategic AI Partnerships Strengthen Competitive Edge

IQVIA leaned heavily into its AI narrative, noting it was named the number one generative AI leader in life sciences by Everest Group and has designated Amazon Web Services as its preferred generative AI cloud provider. The company also highlighted a multi-year partnership with NVIDIA and the deployment of more than 150 AI agents across over 30 use cases, positioning its data and analytics platform as a key differentiator for clients.

Targeted M&A Expands Capabilities and Scale

Management emphasized that 2025 acquisitions were highly focused on extending capabilities in high-value niches, including Phase I trials, early-stage oncology site networks, and patient solutions via Federate Technologies. IQVIA also acquired Cedar Gate, which brought payer and provider analytics capabilities and is expected to contribute approximately $125 million to $140 million of revenue and around $33 million of adjusted EBITDA in 2024, underpinning future growth.

Commercial Franchise Shows Resilience

Commercial operations remained a pillar of stability, with TAS and Commercial revenue up 9.8% reported and 7.1% in constant currency in Q4, despite broader macro uncertainty. Guidance for 2026 Commercial Solutions revenue of $7.2 billion to $7.3 billion implies roughly 7% to 9% growth, underscoring continued demand for IQVIA’s commercial data, analytics, and engagement offerings.

Recognition and Talent Support Brand Strength

The company’s culture and reputation were also front and center, as IQVIA was named one of the world’s most admired companies by Fortune for the ninth straight year. It also ranked first in its category for the fifth consecutive year, reinforcing its standing as an employer of choice and a trusted partner for biopharma and healthcare customers worldwide.

Macro Headwinds and Funding Pressures Linger

Despite better recent trends, management acknowledged that macroeconomic and policy uncertainty, alongside elevated interest rates, weighed on customer decision-making earlier in the year and slowed biotech funding. These pressures dampened R&D bookings earlier in 2025, though the strong year-end recovery suggests that demand is normalizing as clients adjust to the new funding environment.

Cancellations Tick Above Normal in Q4

One blemish on the otherwise solid quarter was slightly higher-than-normal cancellations, which partially offset strong bookings momentum. Management attributed these cancellations mainly to idiosyncratic trial issues rather than systemic demand weakness, suggesting limited read-through to the broader pipeline but a factor to monitor in coming quarters.

Margin Pressure from Pass-Throughs and Mix

While adjusted EBITDA reached $1.046 billion in Q4, up 5%, full-year adjusted EBITDA increased only 2.8% to $3.788 billion, lagging revenue growth and highlighting margin compression. Leaders cited strong pass-through revenue growth and an unfavorable product mix as key drivers and guided investors to expect broadly flat EBITDA margins into 2026, tempering near-term profitability upside.

High Leverage and Rising Interest Expense

IQVIA closed the year with gross debt of $15.724 billion, net debt of roughly $13.745 billion, and net leverage of 3.63 times trailing 12-month adjusted EBITDA, keeping leverage elevated versus many peers. The 2026 outlook includes about $760 million in net interest expense, roughly $80 million higher than 2025, reflecting recent debt issuance and refinancing activity and limiting some of the EPS benefit from operating growth.

Growth Helped by Acquisitions

Management was transparent that acquisitions contributed around two percentage points to Q4 reported revenue growth and roughly five points to CSMS growth, underscoring the role of deal-making in the company’s growth algorithm. While these deals enhance capabilities and scale, investors will be watching for continued strong organic growth to validate the strategy and ensure returns justify the rising interest burden.

COVID Step-Down Normalizes R&D Baseline

R&D Solutions results also reflected a step-down in COVID-related work, as pandemic-era projects and testing volumes continued to unwind and reduce reported growth. Excluding COVID effects, underlying R&D growth looked stronger, suggesting the franchise is performing well on a normalized basis even as a meaningful prior tailwind has now largely rolled off.

Forward-Looking Guidance and Outlook

Within its 2026 framework, IQVIA expects Commercial Solutions revenue of $7.2 billion to $7.3 billion, implying mid- to high-single-digit growth, while R&D Solutions is projected at $9.9 billion to $10.0 billion, roughly 4% growth at the midpoint. For the first quarter, management guided adjusted EBITDA to $920 million to $940 million and adjusted diluted EPS between $2.77 and $2.80, framing a steady start to the year as the company invests in AI and integration while managing cost and interest headwinds.

IQVIA’s earnings call painted a picture of a business regaining momentum, anchored by strong R&D bookings, resilient commercial demand, and growing AI capabilities, even as margin and leverage challenges persist. For investors, the story is one of solid, visible growth with a clear technology edge, balanced against tighter financial flexibility and the need to translate record backlog and AI investments into sustained, high-quality earnings expansion.